Literature DB >> 34260139

Feasibility and acceptability of a home-based resistance training intervention in adolescent and young adult hematopoietic cell transplant survivors.

Tyler G Ketterl1,2,3, Sheri Ballard3, Miranda C Bradford4, Eric J Chow1,2,3, Kari Jenssen3, Sam Myers5, Abby R Rosenberg1,2,3, Matt Van Doren5, K Scott Baker1,2,3.   

Abstract

BACKGROUND: Adolescent and young adult (AYA) hematopoietic cell transplantation (HCT) survivors are at increased risk of metabolic syndrome and lean body mass (LBM) deficits. Resistance training (RT) is a potential intervention to improve LBM, metabolic fitness, and reduce risk of cardiovascular disease. PROCEDURE: Eligible participants ages 13-39 years, 80-120 days post-HCT, transfusion independent, and prednisone dose ≤1 mg/kg/day were approached. Baseline assessments of body composition (DXA), anthropometrics, and strength testing were completed and participants were taught a 12-week, home-based RT intervention with weekly remote coaching. Follow-up assessments were at day +200 (FU1) and +365 post-HCT (FU2). Feasibility targets were (a) 60% enrollment of approached patients, (b) 80% completion of weekly phone calls, and (c) 80% completion of the RT intervention and FU1 assessments. Acceptability was based on positive responses in qualitative interviews.
RESULTS: Twenty of 31 (65%) eligible AYAs enrolled. Three participants failed to complete baseline measurements (2 = scheduling barriers, 1 = passive refusal) and four participants who completed baseline assessments did not receive the intervention (1 = medical reasons, 2 = no longer interested). Of those who completed baseline assessments, 13 received the intervention, completed 88.5% of coaching calls, and 11 (65%) completed FU1. LBM (kg) increased or remained unchanged in nine of nine participants with complete body composition data at FU1 (mean 1.1 kg; 95%CI: 0.4, 1.9). All participants who completed FU1 reported they would recommend the intervention to an AYA HCT survivor.
CONCLUSIONS: A home-based RT intervention in AYA HCT survivors early post HCT is both feasible and acceptable and may maintain or increase LBM.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  adolescent and young adult; resistance training

Mesh:

Year:  2021        PMID: 34260139      PMCID: PMC8463478          DOI: 10.1002/pbc.29206

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  35 in total

1.  Strength Training to Enhance Early Recovery after Hematopoietic Stem Cell Transplantation.

Authors:  Eileen Danaher Hacker; Eileen Collins; Chang Park; Tara Peters; Pritesh Patel; Damiano Rondelli
Journal:  Biol Blood Marrow Transplant       Date:  2016-12-29       Impact factor: 5.742

2.  Comparison of changes in lean body mass with a strength- versus muscle endurance-based resistance training program.

Authors:  Salvador Vargas; Jorge L Petro; Ramón Romance; Diego A Bonilla; Miguel Ángel Florido; Richard B Kreider; Brad J Schoenfeld; Javier Benítez-Porres
Journal:  Eur J Appl Physiol       Date:  2019-01-24       Impact factor: 3.078

3.  Outcomes of allogeneic hematopoietic cell transplantation for adolescent and young adults compared with children and older adults with acute myeloid leukemia.

Authors:  Navneet S Majhail; Ruta Brazauskas; Anna Hassebroek; Christopher N Bredeson; Theresa Hahn; Gregory A Hale; Mary M Horowitz; Hillard M Lazarus; Richard T Maziarz; William A Wood; Susan K Parsons; Steven Joffe; J Douglas Rizzo; Stephanie J Lee; Brandon M Hayes-Lattin
Journal:  Biol Blood Marrow Transplant       Date:  2011-10-29       Impact factor: 5.742

4.  Physical Activity, Fitness, and Cardiometabolic Risk Factors in Adult Survivors of Childhood Cancer with a History of Hematopoietic Cell Transplantation.

Authors:  Megan E Slater; Julia Steinberger; Julie A Ross; Aaron S Kelly; Eric J Chow; Ildiko H Koves; Paul Hoffmeister; Alan R Sinaiko; Anna Petryk; Antoinette Moran; Jill Lee; Lisa S Chow; K Scott Baker
Journal:  Biol Blood Marrow Transplant       Date:  2015-04-10       Impact factor: 5.742

5.  Effects of an outpatient physical exercise program on hematopoietic stem-cell transplantation recipients: a randomized clinical trial.

Authors:  R H Knols; E D de Bruin; D Uebelhart; G Aufdemkampe; U Schanz; F Stenner-Liewen; F Hitz; C Taverna; N K Aaronson
Journal:  Bone Marrow Transplant       Date:  2010-12-06       Impact factor: 5.483

6.  Muscular strength and cardiorespiratory fitness is associated with higher insulin sensitivity in children and adolescents.

Authors:  Amanda C Benson; Margaret E Torode; Maria A Fiatarone Singh
Journal:  Int J Pediatr Obes       Date:  2006

7.  Adipokines, Inflammation, and Adiposity in Hematopoietic Cell Transplantation Survivors.

Authors:  Tyler G Ketterl; Eric J Chow; Wendy M Leisenring; Pam Goodman; Ildi H Koves; Anna Petryk; Julia Steinberger; K Scott Baker
Journal:  Biol Blood Marrow Transplant       Date:  2017-12-25       Impact factor: 5.742

8.  Chronic health conditions in adult survivors of childhood cancer.

Authors:  Kevin C Oeffinger; Ann C Mertens; Charles A Sklar; Toana Kawashima; Melissa M Hudson; Anna T Meadows; Debra L Friedman; Neyssa Marina; Wendy Hobbie; Nina S Kadan-Lottick; Cindy L Schwartz; Wendy Leisenring; Leslie L Robison
Journal:  N Engl J Med       Date:  2006-10-12       Impact factor: 176.079

9.  Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.

Authors:  Kevin C Oeffinger; Ann C Mertens; Charles A Sklar; Yutaka Yasui; Thomas Fears; Marilyn Stovall; Terry A Vik; Peter D Inskip; Leslie L Robison
Journal:  J Clin Oncol       Date:  2003-04-01       Impact factor: 50.717

10.  Effects of elastic resistance exercise on body composition and physical capacity in older women with sarcopenic obesity: A CONSORT-compliant prospective randomized controlled trial.

Authors:  Chun-De Liao; Jau-Yih Tsauo; Li-Fong Lin; Shih-Wei Huang; Jan-Wen Ku; Lin-Chuan Chou; Tsan-Hon Liou
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.